Upregulation of interleukin-12 and -17 in active inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 38, Issue 2, 2003, Pages 180-185

  Nielsen, Ole Haagen ^a   Kirman, I ^b   Rudiger N ^b   Hendel, J ^b   Vainer, B ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE

Author keywords

Crohn disease; Gene expression; Inflammation; Interleukin 12; Interleukin 17; Macrophages; T cells; Ulcerative colitis

Indexed keywords

CD4 ANTIGEN; CHLORDANE; INTERLEUKIN 12; INTERLEUKIN 17; MESSENGER RNA;

ADULT; AGED; ARTICLE; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; INFLAMMATION; LAMINA PROPRIA; MACROPHAGE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CD4-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; GENE EXPRESSION; HUMANS; INTERLEUKIN-12; INTERLEUKIN-17; MACROPHAGES; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 0037299902     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365520310000672     Document Type: Article

References (45)

1. Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol 1996;31 Suppl 216:149-59.
2. Murata Y, Ishiguro Y, Itoh J, Munakata A, Yoshida Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol 1995;30:56-60.
3. Panja A, Goldberg S, Eckmann L, Krishen P, Mayer L. The regulation and functional consequence of proinflammatory cytokine binding on human intestinal epithelial cells. J Immunol 1998;161:3675-84.
4. Schreiber S, Nikolaus S, Hampe J, Hamling J, Koop I, Groessner B, et al. Tumour necrosis factor alpha and interleukin 1β in relapse of Crohn's disease. Lancet 1999;353:459-61.
5. Kosiewicz MM, Nast CC, Krishnan A, Rivera-Nieves J, Moskaluk CA, Matsumoto S, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001;107:695-702.
6. Mariani P, Bachetoni A, D'Alessandro M, Lomanto D, Mazzocchi P, Speranza V. Effector Th-1 cells with cytotoxic function in the intestinal lamina propria of patients with Crohn's disease. Dig Dis Sci 2000;45:2029-35.
7. Blumberg RS, Saubermann LJ, Strober W. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 1999;11:648-56.
8. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998;8:275-83.
9. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995;13:251-76.
10. Scheicher CM, Mehlig M, Dienes HP, Reske K. Uptake of microparticle-absorbed protein antigen by bone marrow dendritic cells results in upregulation of interleukin-1 and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol 1995;25:1566-72.
11. Neurath MF, Fuss I, Kelsall BL, Stuber E, Strober W. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995;182:1281-90.
12. Omata F, Birkenbach M, Matsuzaki S, Christ AD, Blumberg RS. The expression of IL-12 p40 and its homologue, Epstein-Barr virus-induced gene 3, in inflammatory bowel disease. Inflamm Bowel Dis 2001;7:215-20.
13. Monteleone G, Biancone L, Marasco R, Morrone G, Marasco O, Luzza F, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology 1997;112:1169-78.
14. Parronchi P, Romagnani P, Annunziato F, Sampognaro S, Becchio A, Giannarini L, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-32.
15. Rouvier E, Luciani MF, Mattei MG, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpes virus saimiri gene. J Immunol 1993;150:5445.
16. Trobonjaca Z, Leithauser F, Moller P, Bluethmann H, Koezuka Y, MacDonald HR, et al. MHC-II-independent CD4+ T cells induce colitis in immunodeficient RAG-/- hosts. J Immunol 2001;166:3804-12.
17. Simpson SJ, Mizoguchi E, Allen D, Bhan AK, Terhorst C. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol 1995;25:2618-25.
18. Brimnes J, Reimann J, Nissen M, Claesson M. Enteric bacterial antigens activate CD4+ T cells from scid mice with inflammatory bowel disease. Eur J Immunol 2001;31:23-31.
19. Stronkhorst A, Radema S, Yong SL, Bijl H, ten Berge IJ, Tytgat GN, van Deventer SJ. CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. Gut 1997;40:320-7.
20. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999;162:1246-51.
21. Kawaguchi M, Kokubu F, Kuga H, Matsukura S, Hoshino H, Ieki K, et al. Modulation of bronchial epithelial cells by IL-17. J Allergy Clin Immunol 2001;108:804-9.
22. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonist effects with IFN-gamma and TNF-alpha. J Immunol 1999;162:494-502.
23. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995;155:5483-6.
24. Kennedy J, Rossi DL, Zurawski SM, Vega F, Kastelein RA, Wagner JL, et al. Interleukin-17 up-regulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum 1997;40:1050-3.
25. Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol 1991;26:1247-56.
26. Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-1987: a sixfold increase in incidence. Scand J Gastroenterol 1992;27:609-14.
27. Thompson WG. Irritable bowel syndrome: pathogenesis and management. Lancet 1993;341:1569-72.
28. Tvede M, Bondesen S, Nielsen OH, Rasmussen SN. Serum antibodies to Bacteroides species in chronic inflammatory bowel disease. Scand J Gastroenterol 1983;18:783-9.
29. Chomczynski P. A reagent for the single-step simultaneous isolation of RNA, DNA and proteins from cell and tissue samples. Biotechniques 1993;15:532-7.
30. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7 Suppl 1:S30-3.
31. Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 2001;7 Suppl 1:S17-22.
32. Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, et al. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 2001;49:42-6.
33. Kappeler A, Mueller C. The role of activated cytotoxic T cells in inflammatory bowel disease. Histol Histopathol 2000;15:167-72.
34. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. Interleukin-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001;108:430-8.
35. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by rheumatoid synovium. Arthritis Rheum 1999;42:963-70.
36. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999;5:101-4.
37. Teunissen MBM, Koomen CW, de-Waal-Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-9.
38. Mahida YR. The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 2000;6:21-33.
39. Strober W, Fuss I, Kitani A. Regulation of experimental mucosal inflammation. Acta Odontol Scand 2001;59:244-7.
40. Duchmann R, Schmitt E, Knolle P. Meyer-zum-Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-8.
41. Sandborn WJ, Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-608.
42. Kehlen A, Thiele K, Riemann D, Rainov N, Langner J. Interleukin-17 stimulates the expression of IkappaB alpha mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J Neuroimmunol 1999;101:1-6.
43. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S. Interleukin-17. Int Rev Immunol 1998;16:541-51.
44. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts: a possible role as a 'fine-tuning cytokine' in inflammation. Arthritis Rheum 2001;44:2176-84.
45. Kawaguchi M, Kokobu F, Kuga H, Matsukura S, Hoshino H, Ieki K, et al. Modulation of bronchial epithelial cells by interleukin-17. J Allergy Clin Immunol 2001;108:804-9.